Immutep Ltd
IMMP
查看详细走势图
2.860USD
-0.070-2.39%
收盘 12/31, 16:00（美东）报价延迟15分钟
4.18B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.39%
5天
-7.14%
1月
+40.89%
6月
+74.39%
今年开始到现在
0.00%
1年
+31.80%
查看详细走势图
TradingKey Immutep Ltd股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Immutep Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
2
位分析师
强力买入
评级
8.288
目标均价
+265.12%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Immutep Ltd亮点
亮点风险
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
业绩增长期
公司处于发展阶段，最新年度总收入92.04K美元
利润高增长
公司净利润处于行业前列，最新年度总收入92.04K美元
估值合理
公司最新PE估值-31.81，处于3年历史合理位
机构减仓
最新机构持股2.80M股，环比减少20.90%
Immutep Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Immutep Ltd简介
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
公司代码IMMP
公司Immutep Ltd
CEOVoigt (Marc)
网址https://www.immutep.com/
常见问题
Immutep Ltd(IMMP)的当前股价是多少？
Immutep Ltd(IMMP)的当前股价是 2.860。
Immutep Ltd的股票代码是什么？
Immutep Ltd的股票代码是IMMP。
Immutep Ltd股票的52周最高点是多少？
Immutep Ltd股票的52周最高点是3.530。
Immutep Ltd股票的52周最低点是多少？
Immutep Ltd股票的52周最低点是1.320。
Immutep Ltd的市值是多少？
Immutep Ltd的市值是4.18B。
Immutep Ltd的净利润是多少？
Immutep Ltd的净利润为-61.43M。
现在Immutep Ltd(IMMP)的股票是买入、持有还是卖出？
根据分析师评级，Immutep Ltd(IMMP)的总体评级为--，目标价格为8.288。
Immutep Ltd(IMMP)股票的每股收益（EPS TTM）是多少
Immutep Ltd(IMMP)股票的每股收益（EPS TTM）是-0.064。
相关品种
